X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

SLN

Closed

Silence Therapeutics Plc

5.92
+0.12 (+2.07%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 5.8
Day's Range: 5.765 - 6.035
Send
When Written:
 
6.16
Silence Therapeutics PLC is a biotechnology company that is focused on developing and commercializing RNA interference (RNAi) therapeutics for the treatment of various diseases. The company was founded in 1998, and it is headquartered in London, United Kingdom.

Silence Therapeutics' proprietary technology platform, known as AtuRNAi, allows for the design and development of highly specific RNAi therapeutics that can target and silence disease-causing genes. The company is currently conducting clinical trials for its lead product candidate, SLN124, which is being developed for the treatment of iron overload disorders.

In addition to SLN124, Silence Therapeutics has a pipeline of other RNAi therapeutics in various stages of development for the treatment of diseases such as cancer, cardiovascular disease, and metabolic disorders.

Silence Therapeutics is listed on the London Stock Exchange under the ticker symbol "SLN." The company has partnerships with several pharmaceutical companies, including AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda Pharmaceutical Company Limited.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X